@inproceedings{inproceedings, title  = {{Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial}},

 url = {{}},

 year = {{2018}},

 month = {{4}},

 author = {{Burt RK and Balabanov R and Snowden JA and Sharrack B and Oliveira MC and Burman J}},

 volume = {{90}},

 journal = {{NEUROLOGY}},

 note = {{Accessed on 2024/12/22}}}